How can we deliver on the promise of precision medicine in oncology and beyond? A practical roadmap for action

被引:5
作者
Baird, Anne-Marie [1 ,2 ]
Westphalen, C. Benedikt [3 ,4 ]
Blum, Sandra [2 ,5 ]
Nafria, Begonya [2 ,6 ,7 ]
Knott, Tanya [2 ,8 ]
Sargeant, Ify [9 ]
Harnik, Helena [2 ,10 ,12 ]
Brooke, Nicholas [2 ,10 ]
Wicki, Nicole [2 ,10 ]
Wong-Rieger, Durhane [2 ,11 ]
机构
[1] Lung Canc Europe LuCE, Bern, Switzerland
[2] The Synergist, Testing Targeted Treatments Program Team FT3, Brussels, Belgium
[3] Ludwig Maximilians Univ Munchen, Univ Hosp, Comprehens Canc Ctr Munich, Munich, Germany
[4] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Med 3, Munich, Germany
[5] Roche, Basel, Switzerland
[6] Inst Recerca St Joan de Deu, Barcelona, Spain
[7] Hosp St Joan de Deu Pg, Innovat & Res Dept, Barcelona, Spain
[8] Sarah Jennifer Knott SJK Fdn, Dublin, Ireland
[9] Twist Med, Burlingame, CA USA
[10] The Synergist, Brussels, Belgium
[11] Canadian Org Rare Disorders, Toronto, ON, Canada
[12] The Synergist, Testing Targeted Treatments Program FT3, Ave Louise 231, B-1050 Brussels, Belgium
关键词
collaborative precision medicine; equitable access precision medicine; patient engagement; precision medicine; GENOMICS; PATIENT;
D O I
10.1002/hsr2.1349
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
BackgroundPrecision medicine (PM) is a form of personalized medicine that recognizes that individuals with the same condition may have different underlying factors and uses molecular information to provide tailored treatments. This approach can improve treatment outcomes and transform lives through favorable risk/benefit ratios, avoidance of ineffective interventions, and possible cost savings, as evidenced in the field of lung cancer and other oncology/therapeutic settings, including cardiac disease, diabetes, and rare diseases. However, the potential benefits of PM have yet to be fully realized. DiscussionThere are many barriers to the implementation of PM in clinical practice, including fragmentation of the PM landscape, siloed approaches to address shared challenges, unwarranted variation in availability and access to PM, lack of standardization, and limited understanding of patients' experience and needs throughout the PM pathway. We believe that a diverse, intersectoral multistakeholder collaboration, with three main pillars of activity: generation of data to demonstrate the benefit of PM, education to support informed decision-making, and addressing barriers across the patient pathway, is necessary to reach the shared goal of making PM an accessible and sustainable reality. Besides healthcare providers, researchers, policymakers/regulators/payers, and industry representatives, patients in particular must be equal partners and should be central to the PM approach?from early research through to clinical trials and approval of new treatments?to ensure it represents their entire experience and identifies barriers, solutions, and opportunities at the point of delivery. ConclusionWe propose a practical and iterative roadmap to advance PM and call for all stakeholders across the healthcare system to employ a collaborative, cocreated, patient-centered methodology to close gaps and fully realize the potential of PM.
引用
收藏
页数:10
相关论文
共 71 条
  • [1] Artificial intelligence with multi-functional machine learning platform development for better healthcare and precision medicine
    Ahmed, Zeeshan
    Mohamed, Khalid
    Zeeshan, Saman
    Dong, Xinqi
    [J]. DATABASE-THE JOURNAL OF BIOLOGICAL DATABASES AND CURATION, 2020,
  • [2] Scaling Genetic Counseling in the Genomics Era
    Amendola, Laura M.
    Golden-Grant, Katie
    Scollon, Sarah
    [J]. ANNUAL REVIEW OF GENOMICS AND HUMAN GENETICS, VOL 22, 2021, 2021, 22 : 339 - 355
  • [3] [Anonymous], 2019, ERRATUM PHARMACOECON, V37, P117
  • [4] [Anonymous], 2020, ERRATUM VALUE HLTH, V23, P1522
  • [5] [Anonymous], 2023, apnews16 Apr
  • [6] Association of Community Cancer Centers (ACCC), 2023, PREC MED
  • [7] Association of Community Cancer Centers (ACCC), 2023, BIOMARKERLIVE TOOLK
  • [8] Beans Julie A, 2020, AJOB Empir Bioeth, V11, P246, DOI 10.1080/23294515.2020.1817172
  • [9] Integrating precision cancer medicine into healthcare-policy, practice, and research challenges
    Bertier, Gabrielle
    Carrot-Zhang, Jian
    Ragoussis, Vassilis
    Joly, Yann
    [J]. GENOME MEDICINE, 2016, 8
  • [10] Brookings Institute, 2023, ADV PREC MED AG GOV